8th March, to promote cooperation and synergy in the ecosystem, HLC and Temasek gathered with ecosystem companies at Viva Biotech's headquarters in Shanghai for a special event.

The event brought together over 50 biopharmaceutical companies specializing in CXO, Biotech, Life Sciences, and various other fields. Its primary objective was to provide a collaborative platform for ecosystem enterprises, fostering enhanced interaction and cooperation among them. It ultimately aimed to drive the advancement of the biopharmaceutical industry.

During the event, senior management of HLC and Temasek delivered opening speeches; Dr. Chen Mao, Chairman of Viva Biotech，delivered a speech as the host of the event; Dr. Xiaoping Ye, Chairman of Tigermed, and Wei Jiang, Director of Hongene Biotech, delivered a speech on behalf of the ecosystem enterprises; and Shuguang Wang, a member of the Management Committee of CICC, delivered a speech.

Dr. Cheney Mao, Chairman and Chief Executive Officer of Viva Biotech

As the host of this event, Dr. Mao said that at the current moment, true invincible innovation can only be achieved when all resources capitalize on each other's strengths, integrating and flowing together. What we need most is to establish a biotech ecosystem, embrace the warmth of the group to achieve a win-win situation, and do not recommend fighting alone, which is especially important in the winter period.

Founded with a focus on structure-based small molecule drug discovery, Viva Biotech has become a one-stop CRDMO service provider, with R&D and production layouts in 5 regions in China, which can provide services to more and more biotech companies.

Dr. Xiaoping Ye, Co-founder and Chairman of Tigermed

Tigermed is confident about the future and focused on investing in biopharmaceutical projects, whether they involve publicly traded corporations or subsidiary funds under Tigermed. From a long-term perspective, the prospects for any sub-sector or stage within biopharmaceuticals are promising.

As an industry fund, the subsidiary funds under Tigermed consistently focus on long-term planning, capable of withstanding market fluctuations. Since 2015, we have invested in hundreds of projects. Over the past few years, we have witnessed rapid improvements in the innovation capabilities of Chinese companies, which is extremely encouraging. Moving forward, we will stay true to our aspirations, joining hands with numerous CROs and entrepreneurial companies in the innovative pharmaceutical sector, warming each other, and providing mutual support.

Wei Jiang, Chairman of Hongene Biotech

As a contract development and manufacturing organization (CDMO) company, Hongene Biotech will not only provide mature experience, team, and equipment but also make efforts on the technology platform to provide the best R&D service, which is also our important mission in the future. Hongene Biotech will do further R&D towards cost reduction while doing a good job in the material stability of mini-nucleic acid drugs, hoping to be able to stick with peer companies in the cycle and promote the development of the industry.

Jingwen Miao, Managing Director, Investment (China), Temasek

Initially, innovative Chinese pharmaceutical companies primarily relied on licensing in. Later, a few sporadic instances of licensing out emerged. However, now multinational corporations (MNCs) have begun extensive collaboration and investment within China. There is no doubt that China's innovative pharmaceutical industry has stepped onto the international stage. Compared to innovative drugs, Contract Research and Development Manufacturing Organizations (CRDMOs) have taken an earlier leap onto the global stage and play a significant role in the global innovative pharmaceutical sector.

Hui Wang, CEO of Highlight Capital

Despite the challenging environment, we cannot succumb to adversity. HLC is committed to wholeheartedly supporting everyone's progress. Together, we will weather every storm and overcome every obstacle, reaching the summit and reflecting upon the journey we have taken. I encourage all Biotech companies to take inspiration from Viva Biotech's growth from humble beginnings and strive for excellence.

Shuguang Wang, Head of Investment Banking and Member of Management Committee, CICC

While the healthcare industry has faced challenges in the capital markets and changes in regulatory policies over the past few years, there has been a lot of good news at the same time, such as the series of heavyweight License-out deals struck by domestic Biotech at the end of last year. All in all, what we need to do in this environment is to find allies, work hand in hand, and support each other, regardless of the momentary gains and losses, and together we can "catch" the next bull market and get a long-term win-win situation.

Event photo

Subsequently, Jin Zhang, Deputy General Manager of CICC and Chief Analyst of the Pharmaceutical and Biotechnology Industry of the Research Department, shared the industry of "Recent Global Innovative Drug Financing and CXO Development Trends" for the participating ecosystem enterprises. More than 20 companies conducted on-site roadshows and exchanges on business cooperation and matchmaking.

As one of the representatives of CXOs and life science companies, Dr. Derek Ren, CEO of Viva Biotech Shanghai, shared the company's history and milestones, noting that Viva Biotech has grown into a one-stop integrated service platform from early structure-based drug discovery and development to commercial drug manufacturing, and highlighted Viva Biotech's structure-focused CRO drug discovery and development services.

Leveraging its strong capabilities in protein production and structural research, Viva Biotech has flexibly applied multiple technologies such as V-DEL, ASMS, Intact-MS, SPR, and Crystal soaking, all built upon the foundation of its proprietary compound libraries. The company also offers both non-covalent and covalent compound screening, followed by validation through its Bioassay platform. Integration with medicinal chemistry, chemical synthesis and preparation, chiral separation, and preparation in chemical analysis, alongside drug metabolism studies, culminates in a comprehensive drug development system. Within this system, Viva Biotech has further incorporated Computer-Aided Drug Design (CADD) and Artificial Intelligence-Driven Drug Design (AIDD) to guide the optimization and mechanism of action studies for compounds. This approach efficiently and precisely drives the entire new drug discovery process.

Finally, Dr. Ren emphasized the one-stop comprehensive service capability of Viva Biotech, which provides differentiated and customized services for global biotech and pharmaceutical enterprises with years of experience and unique advantages in FIC drug R&D, as well as the professional leadership of a team of senior scientists.

Other CXOs and life science companies expressed their willingness to cooperate and communicate with entrepreneurs at the meeting and their expectations from their main business, core products, development strategy and competitive advantages; biotech companies made detailed introduction and full communication on their pipeline layout, clinical data, and advantages of technology platform. Various biotech companies with their bright data and promising clinical progress.